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Abstract
Background: Health policy and planning depend on quantitative data of disease epidemiology.
However, empirical data are often incomplete or are of questionable validity. Disease models
describing the relationship between incidence, prevalence and mortality are used to detect data
problems or supplement missing data. Because time trends in the data affect their outcome, we
compared the extent to which trends and known data problems affected model outcome for breast
cancer.
Methods: We calculated breast cancer prevalence from Dutch incidence and mortality data (the
Netherlands Cancer Registry and Statistics Netherlands) and compared this to regionally available
prevalence data (Eindhoven Cancer Registry, IKZ). Subsequently, we recalculated the model
adjusting for 1) limitations of the prevalence data, 2) a trend in incidence, 3) secondary primaries,
and 4) excess mortality due to non-breast cancer deaths.
Results: There was a large discrepancy between calculated and IKZ prevalence, which could be
explained for 60% by the limitations of the prevalence data plus the trend in incidence. Secondary
primaries and excess mortality had relatively small effects only (explaining 17% and 6%,
respectively), leaving a smaller part of the difference unexplained.
Conclusion: IPM models can be useful both for checking data inconsistencies and for
supplementing incomplete data, but their results should be interpreted with caution. Unknown data
problems and trends may affect the outcome and in the absence of additional data, expert opinion
is the only available judge.
Background
Estimates of disease-specific incidence, prevalence and
mortality, specified by age and sex, are important infor-
mation to health care policy and planning. They are essen-
tial inputs to cost-effectiveness analyses and burden of
disease calculations. Empirical data, however, are often
difficult to obtain or are of questionable validity. To rem-
edy some of these data problems, disease models have
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epidemiological parameters, by exploiting the causal
structure of a disease. Incidence, prevalence, mortality
models (IPM models) formalise the relationship between
the three parameters, using the fact that incidence has to
precede prevalence, and that cause-specific mortality can
only follow disease. IPM models have been used frequent-
ly both to supplement missing data and to study the
agreement between different epidemiological data [1–4].
Our previous study supported the formal validity of IPM
models, but when the modelling was applied to empirical
data on four types of cancer, the model calculations dif-
fered to a large extent from the empirical data [5]. For
breast cancer the difference was particularly large. It was
argued that these discrepancies may indicate inconsisten-
cies in the data, but that they may also be caused by time
trends.
When the data for one disease are not in accordance with
each other, they are internally inconsistent. Inconsisten-
cies may be caused by differences in the completeness of
the data. For example, when more incident cases are
missed than deaths, incidence and mortality are inconsist-
ent. Also, inconsistencies may arise when the data were
derived from different contexts (e.g. a different region) or
measured differently (e.g. varying case-definitions). Ap-
plying inconsistent incidence and mortality to an IPM
model will result in under- or overestimating prevalence,
and thus in discrepancies between model estimations and
empirical prevalence data. Time trends, on the other
hand, may cause the data to appear inconsistent in a
steady state model, while in fact they are not. Because
prevalence is the resultant of incident cases from the past,
it cannot react instantaneously to changes in incidence
and case-fatality, but only with a certain delay. It is possi-
ble to account for the effects of time trends in a dynamic
model, but this requires additional input data on the na-
ture and size of the trends, which are not available for
most diseases. Often, we do not even know whether a
trend is present or not, and the researcher faces a dilemma
what to do with the discrepancies. Adjusting observed
data for apparent inconsistencies that are in fact the con-
sequence of past trends would rather defeat the purpose of
IPM models.
For breast cancer in the Netherlands the discrepancy be-
tween observed prevalence and prevalence calculated
from incidence and mortality was particularly large [5].
Fortunately, for breast cancer several data problems are
known, and, in addition, there is a tentative estimate of
the trend in incidence. This allowed us to quantify the rel-
ative contribution of the trend and several known data
problems on the discrepancy and to throw some light
upon the researcher's dilemma. Even though prevalence
of breast cancer is not a very useful epidemiological meas-
ure, it does allow us to illustrate the difficulties in the use
of IPM modelling because of the relative abundance of
data.
Methods
General approach
We calculated the point-prevalence of breast cancer in the
Netherlands and its 95 % confidence interval from na-
tional incidence rates and cause-specific mortality rates
using the IPM model described by Barendregt et al. [6].
We compared it to regional prevalence data. To determine
the separate effects of trends and known data problems we
next recalculated the model:
a) incorporating the incompleteness in the prevalence
data (see below),
b) adjusting for a trend in incidence,
c) adjusting for double counting of incident women with
secondary primaries, and
d) taking excess mortality from non-breast cancer deaths
into account.
For point c a single cohort model was used, while for a, b,
and d it was necessary to use a multi-cohort model that
takes into account both age and calendar time. We esti-
mated the proportion of the difference that was explained
by each of the recalculations from the overall differences
in the number of prevalent cases using 1993 population
figures and summing over all age groups.
IPM model
Our model is based upon the conceptual disease model
depicted in Figure 1 and was described in Kruijshaar et al.
[5]. Briefly, the model describes a population as being in
two states: diseased or susceptible, while transition haz-
ards determine how people move from one state to anoth-
er. Following an initially disease-free cohort over time and
applying the transition hazards, the number of cases can
be calculated. Under the important assumption of a
steady-state situation, time is equivalent to age. The mod-
el then allows the calculation of prevalence at a certain age
from the prevalence at the previous age and the transition
hazards. By assuming furthermore equal mortality from
other causes in cases and susceptibles, prevalence at exact
age n can be calculated from incidence and cause-specific
mortality probabilities using formula 1a in the Appendix
See additional file: 1 [6].
Baseline calculation
First, we calculated prevalence from national incidence
and mortality rates of female breast cancer (ICD-9 code
174) for 1991–1995, averaged by five-year age groups upPage 2 of 8
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Cancer Registry (NKR) are based on pathology and hospi-
tal admission data, and the mortality data from Statistics
Netherlands (CBS) on death certificates. To enable com-
parison with the prevalence data we used incidence rates
excluding in-situ tumours. Incidence and mortality rates
were first interpolated to one-year age groups using the cu-
bic-spline method and then converted into probabilities
(see the Appendix Additional file: 1 for formulas). A 95%
confidence interval of the calculated prevalence was ob-
tained by parametric bootstrapping assuming a Poisson
distribution for numbers of incident cases and deaths in
each age group. The @risk software programme [7] was
used to simulate 10000 iterations by Monte Carlo
sampling.
The Regional Cancer centre South (IKZ) was the only can-
cer registry in the Netherlands that has estimated preva-
lence. The IKZ determined prevalence for a specific part
(the core region) of the region South at 1-1-1993 by
checking the vital status of all incident cases registered in
the region since 1970 against the municipal population
administration and the National Death Index. If a person
had moved to another municipality in the Netherlands,
data from that municipal population administration was
used (under Dutch law, registration with the municipal
population administration is obligatory within five days
of changing address). In case of migration to another
country, a case was lost to follow up. In-situ tumours are
not included. For more information on these data we refer
to Coebergh et al. [8]. A 95% confidence interval around
these data (by five-year age group up to 85+) was calculat-
ed assuming a binomial distribution (see formula 2 in the
Appendix Additional file: 1 ). Point estimates and confi-
dence intervals were interpolated to one-year age groups
as described in the Appendix Additional file: 1.
Limitations of the prevalence data
Prevalence registered by the IKZ does not include patients
diagnosed before 1970 and is consequently underestimat-
ed. To quantify the effect of this, we created a dynamic
model, incorporating a parameter y that represents the
number of years prior to incidence. Prevalence in the ref-
erence year y0, was calculated from prevalence in the 23
years prior to y0 (see Appendix Additional file: 1).
Also, prevalence data refer to a specific region only, where-
as the model calculations are based on national input. We
showed in our previous study [5], that differences be-
tween regional and national incidence and mortality rates
hardly affected the calculated prevalence. Therefore, we
did not further examine this here.
Trend in incidence
Next, we estimated the effect of a trend of increasing inci-
dence on the calculated prevalence. While incidence in-
creased, the population mortality rate for breast cancer
has remained approximately the same in the Netherlands
[8–12], thus case-fatality must have declined. Coebergh et
al. have estimated the yearly rise in incidence in the region
South between 1975 and 1986, to be approximately one
percent [13]. The effects of screening are not included in
this estimate, as it was not introduced until later, but ef-
fects of other types of increased case finding were included
– if present.
We estimated the effect using the dynamic model de-
scribed above, decreasing incidence by one percent for
Figure 1
A Markov model for cancersPage 3 of 8
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Appendix Additional file: 1). We assumed the trend was
present up to 95 years before the year of reference. Sensi-
tivity to the trend was inspected, by applying a 50% higher
and lower trend (1.5% and 0.5%) as input values.
Double counting incident women with a secondary 
primary
The NKR registers the number of incident tumours,
whereas prevalence refers to women. Women are thus
counted twice, if they have a second primary tumour in
their breast (SP). The percentage of SPs by age group were
provided for 1991–1995 by the IKZ. We estimated the in-
cidence of women with breast cancer, by subtracting the
age-specific proportion SP from the reported incidence
rate and recalculated our model.
Excess mortality from non-breast cancer deaths
Breast cancer patients have been shown to be at increased
risk of dying from other causes of death [14], although
with longer survival (>20 years) they may experience a de-
creased risk [15]. Cause-specific mortality data thus un-
derestimate the total excess mortality from breast cancer.
We adjusted for this estimating excess mortality from du-
ration-specific relative survival data assuming a lognormal
survival distribution from breast cancer and a proportion
not dying from breast cancer (proportion cured) [16], as
described in the Appendix Additional file: 1 (formula 5).
Relative survival data, i.e. excess mortality over and above
the background mortality, were reported by the IKZ regis-
try for three cohorts (1970–1979, 1980–1986 and 1987–
1992) for ages < 70, and > 70 [8]. Because survival im-
proves over time, we used survival probabilities at one,
three and five years after incidence of the youngest 1987–
1992 cohort. As longer follow-up was not available for
this cohort, survival at 10 and 20 years was estimated us-
ing the conditional 10 and 20-year survival in the older
cohorts. Fitting the lognormal model allowed us to esti-
mate the cumulative probability of excess mortality with
time after incidence, from which we calculated the yearly
mortality probability (see Appendix Additional file: 1).
We extended our baseline model to include duration (see
Appendix Additional file: 1  for the mathematical descrip-
tion): prevalence at age n, d years after incidence was cal-
culated from the prevalence at the previous age and year.
Summation across all years d provided age-specific
prevalence.
Results
In our baseline calculation we estimated the prevalence of
breast cancer from national incidence and cause-specific
mortality data. The results of this are shown in black in
Figure 2 (solid line), together with the regional data (dot-
ted line), while the total number of calculated prevalent
cases and the difference with the IK2 are shown in Table
1. Both the IKZ and calculated prevalence increased expo-
nentially with age to about age 47, but thereafter they
started to diverge. The model calculations increased line-
arly to a prevalence of 9.2 % at age 85, while the IKZ prev-
alence increased more slowly and levelled off to 3.7 %. At
age 55 the calculated prevalence was 1.5 times higher than
the data, increasing to 2.5 times at age 85, a difference in
total number of cases of 86%. The 95 % confidence inter-
val for the calculated prevalence was narrow, due to the
high numbers of breast cancer incidences and deaths. The
uncertainty in the prevalence data was larger. From age 48
upward the confidence intervals did not overlap.
Figure 2 and Table 1 also show the effects of the known
data problems and trend in incidence (coloured lines).
First, excluding cases that became incident more than 23
years before the year of reference had the largest effect and
altered the age pattern. Prevalence increased with age
more slowly, levelling off to a maximum of 4.4 % at age
78, and declining thereafter. The total number of preva-
lent cases was 53 % higher than the IKZ prevalence, ex-
plaining 39% of the difference between calculated and
IKZ prevalence. Second, incorporating a secular trend in
incidence in the calculation of prevalence resulted in a
lesser increase with age, levelling off after age 70, without
reaching a plateau. The secular trend of one percent de-
creased the discrepancy with 44% (ranging between 49%
and 18% for 50% higher and lower estimates of the
trend). Third, adjusting for double counting of incident
women with a second primary tumour of the breast (SP)
had a smaller effect. The percentage of SP did not exceed
nine percent for any age group. Subtracting this percent-
age from the incidence rate explained 17% of the differ-
ence. Fourth, taking excess mortality from non-breast
cancer deaths into account made a difference of six
percent.
The combined effect of restricting the duration of preva-
lence and the trends, shown in Figure 3, resulted in a 60%
decrease of the difference (ranging between 70% and 50%
for a 50% higher or lower trend). At age 85 the calcula-
tions touched upon the upper confidence limit of the
data.
Discussion
We quantified the separate effects of known data prob-
lems and a trend in incidence on IPM model calculations
of breast cancer prevalence, and inspected their influence
on the discrepancy between model estimations and prev-
alence data. Two factors had a major effect on the estimat-
ed prevalence: the limitation of the IKZ prevalence data
including only incident cases since 1970, and the trend in
incidence. Together, they accounted for a major part
(60%) of the discrepancy. Still, their combined effectPage 4 of 8
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Calculated prevalence and prevalence data of breast cancer by age. Baseline calculation and separate effects of 
known data problems and trend. Baseline: baseline calculation, 95 % CI: 95 % confidence interval, >1970:excluding incident 
cases of before 1970, 1% trend: estimating the effect of a secular trend in incidence, sensitivity: 50% sensitivity borders around 
the effect of the secular trend, SP: adjusting for secondary primaries, mortality: including excess mortality from non-breast can-
cer deaths.
Table 1: Comparison of the total number of prevalent cases of breast cancer, estimated in different ways, and 1993 prevalence data.
Total number of cases estimated % difference from 1993 data % of the gap explained
1993 data 123216 0.0 0.0
Baseline 66370 85.6 100.0
Combined 89169 34.4 59.9
>1970 101268 52.6 38.6
1% trend 103943 56.6 33.9
SP 113440 70.9 17.2
mortality 119769 80.5 6.1
Baseline: baseline calculation, combined: adjusting for one-% trend and excluding incident cases of before 1970, >1970: excluding incident cases of 
before 1970, 1% trend: estimating the effect of a secular trend in incidence, SP: adjusting for secondary primaries, mortality: including excess mor-
tality from non-breast cancer deaths.
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adjusting for double counting of incident women with
secondary primaries of the breast and of taking excess
mortality from non-breast cancer deaths into account
were small. Consequently, the combined effect of all four
factors does not explain the entire difference. Either un-
known data problems are present contributing to the re-
maining difference, or we underestimated some of the
effects.
The two factors with the largest effects could influence the
calculations because prevalence is a stock variable: it con-
tains cases that became incident in the past. The long sur-
vival time of breast cancer explains why these two factors
can exert such a strong influence. The time lag after which
prevalence fully reflects a change in incidence is deter-
mined by the rate at which the pool of prevalent cases is
replaced by new cases, which, in turn, depends on the sur-
vival time. The underestimation of the prevalence data
due to its limitation to incident cases after 1970 may be as
large as 44 % at age 85, but is lower on average, as the
effect increases with age. When the effect is calculated ad-
ditional to adjusting for the trend in incidence, it is also
smaller: 24 % at age 85. In a small part of the IKZ region
prevalence can be based upon incidence registration since
1958 [9]. These data are indeed higher than the IKZ data
for the larger region indicating the data will improve with
longer follow-up in the future.
The estimated trend in incidence and the effect of adjust-
ing for it are subject to some uncertainty for several rea-
sons. First, the one percent trend is an average figure; its
magnitude differs with age and calendar year. Second, the
regional estimate may deviate somewhat from the nation-
Figure 3
Calculated prevalence and prevalence data of breast cancer by age. Baseline calculation and the effect of both 
the secular trend and restricting prevalence. Baseline: baseline calculation, 95 % CI: 95 % confidence interval, combined: 
adjusting for one-% trend and excluding incident cases of before 1970, sensitivity: the effect of 50% change in the estimated 
trend in incidence on the combined adjustment.







	




       	 	 
 









	


	


	


Page 6 of 8
(page number not for citation purposes)
Population Health Metrics 2003, 1 http://www.pophealthmetrics.com/content/1/1/5al trend. Furthermore, it is a rounded figure. Nevertheless,
as the results of the sensitivity analysis showed that
increasing or decreasing the trend by 50% altered the per-
centage explained by a combined effect (of limiting
prevalence and the secular trend) by only 10%-points, we
expect these three effects to be small. The estimated one
percent may also be too low because it does not include
the effect of the introduction of screening around 1990 in
the Netherlands. We estimated this effect in an additional
analysis, increasing the estimated one percent to five per-
cent for the last four years. The additional effect of screen-
ing was very small. Finally, we may have overestimated
the effect assuming that a one percent trend was present
many years before the period for which it was estimated
(1975 to 1986). Assuming no trend before 1975 in an ex-
tra analysis increased the calculated prevalence by almost
10 % at age 85, but inspection of the incidence rates since
1958 for the smaller part of the IKZ region showed that in-
cidence has increased since 1958 [9]. The effect of assum-
ing no trend before 1960 was negligible.
The effects of adjusting for secondary primaries and excess
mortality were only small, but this is not surprising. The
proportion of women with a secondary primary in the
breast did not exceed nine percent, preventing a much
larger change in the calculated prevalence. Also, the rela-
tive risk of breast cancer patients to die from other causes
of death is not that high, and may even inverse with long-
er follow-up [14,15].
Thus, although the effect of the trend may be somewhat
uncertain, other unknown data problems are likely to
cause the remaining difference between calculated and
IKZ prevalence. One possible explanation for the remain-
ing deviation could be that when the cancer registries
started completeness of incidence was not as high as it is
now. As a result the prevalence is underestimated by the
IKZ. On the other hand, IKZ prevalence was determined
by checking population administrations, which involves
matching of the registrations, which is never 100% accu-
rate. Therefore, some deaths may have been missed and
individuals inaccurately assumed to be alive, resulting in
an overestimation of the IKZ prevalence. How large both
counteracting effects are, is difficult to determine. An ad-
ditional explanation may be found in variation between
national and regional all-cause mortality, as the equations
in our model are based on the assumption of similar back-
ground mortality. A higher background mortality in the
IKZ region would decrease the discrepancy, but we expect
only a minimal effect as the differences in all-cause mor-
tality will be minor. Additional reasons for overestimating
incidence or underestimating mortality (both resulting in
overestimating prevalence) are difficult to think of. Can-
cer incidence data in the Netherlands are reliable with a
completeness of 96.2 % around 1990 [17], and probably
even higher in the years thereafter. Furthermore, mortality
by cause-of-death statistics of the Netherlands are as-
sumed to be reliable and, compared to other European
countries, the detection fraction for deaths from cancer is
high [18]. The causes of the remaining discrepancy thus
remain uncertain.
Conclusions
Even when data are regarded as relatively reliable, as was
the case for breast cancer in the Netherlands, data prob-
lems may be present. 1993 prevalence data for breast can-
cer in the IKZ region are underestimated, as they do not
include incident cases before 1970. Our analyses show the
importance of using IPM modelling to detect data prob-
lems. However, we also showed the trend in incidence to
have a large effect on the model estimations for breast
cancer, complicating the use of IPM models.
IPM models can be useful both for checking for data in-
consistencies and for supplementing incomplete data, but
in both cases there remains the need for careful interpre-
tation of the results. In the all too common situation
where, unlike for breast cancer, no data on the size and
nature of trends are available, the effects of trends cannot
be estimated. Furthermore, unknown data problems may
affect the model estimations in unknown directions. In
the absence of additional data the researcher is faced with
the dilemma of how to interpret model discrepancies, and
expert opinion is the only available judge.
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